- $530.70m
- $418.09m
- $90.40m
- 52
- 13
- 55
- 34
Annual income statement for Urogen Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 11.8 | 48 | 64.4 | 82.7 | 90.4 |
| Cost of Revenue | |||||
| Gross Profit | 10.8 | 42.9 | 56.7 | 73.4 | 81.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 139 | 140 | 143 | 148 | 187 |
| Operating Profit | -127 | -92.3 | -79 | -65.5 | -96.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -125 | -109 | -108 | -98.3 | -124 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -128 | -111 | -110 | -102 | -127 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -128 | -111 | -110 | -102 | -127 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -128 | -111 | -110 | -102 | -127 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.9 | -4.96 | -4.81 | -3.55 | -2.96 |